You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 20, 2025

Details for Patent: 10,610,530


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,610,530 protect, and when does it expire?

Patent 10,610,530 protects OPZELURA and is included in one NDA.

Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has seventy-eight patent family members in forty-one countries.

Summary for Patent: 10,610,530
Title:Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile
Abstract: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentyl- propanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s): Li; Hui-Yin (Hockessin, DE), Rodgers; James D. (Landenberg, PA)
Assignee: Incyte Corporation (Wilmington, DE) Incyte Holdings Corporation (Wilmington, DE)
Application Number:16/003,210
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;
Patent landscape, scope, and claims:

United States Patent 10,610,530: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

The United States Patent 10,610,530, titled "Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile," is a significant patent in the field of pharmaceuticals, particularly in the treatment of diseases associated with Janus kinase (JAK) activity. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Overview

Invention Description

The patent describes salt forms of the compound (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile, which is a Janus kinase inhibitor. These salts are designed for improved stability, solubility, and bioavailability, making them more effective for therapeutic use[4].

Therapeutic Applications

The invention provides methods for treating various diseases, including cancer, skin disorders, and inflammation, by administering these salt forms of the JAK inhibitor. The salts can modulate the activity of JAK1, JAK2, JAK3, or TYK2, with some salts being selective inhibitors of specific JAKs[4].

Scope of the Patent

Claim Analysis

The patent claims are crucial in defining the scope of the invention. Here are some key aspects:

  • Composition Claims: The patent claims various salt forms of the JAK inhibitor, including those formed with maleic acid, sulfuric acid, or phosphoric acid. These claims cover the chemical composition and the process of preparing these salts[4].
  • Method Claims: The patent includes method claims for treating diseases associated with JAK activity by administering the salt forms of the inhibitor. These methods specify the therapeutic applications and the dosages[4].
  • Use Claims: The claims also cover the use of these salts in compositions that include at least one pharmaceutically acceptable carrier, highlighting their applicability in pharmaceutical formulations[4].

Metrics for Patent Scope

Research on patent scope often uses metrics such as independent claim length and independent claim count to measure the breadth of a patent. For this patent, the claims are detailed and specific, indicating a narrower scope that is more focused on the therapeutic applications and the specific salt forms of the JAK inhibitor. This narrow scope can be associated with a higher probability of grant and a shorter examination process, as narrower claims tend to be more clearly defined and less likely to face objections during the examination process[3].

Claims and Their Significance

Independent Claims

The independent claims in this patent are critical as they define the core invention. For example, Claim 1 might describe the salt forms of the JAK inhibitor, while subsequent claims detail the methods of preparation, therapeutic uses, and pharmaceutical compositions.

Dependent Claims

Dependent claims build upon the independent claims, providing additional details and limitations. These claims help to further narrow the scope and ensure that the patent covers specific aspects of the invention without overly broad claims that might be challenged.

Patent Landscape

International Patent Offices

To understand the global reach of this invention, it is essential to search international patent offices. Databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) can be used to see if similar patents have been filed or granted in other countries[1].

Related Patents and Prior Art

The Common Citation Document (CCD) application can be used to consolidate prior art cited by participating IP offices, providing a comprehensive view of related patents and prior art. This helps in understanding the novelty and non-obviousness of the invention[1].

Classification and Citation Data

The patent is classified under various categories such as A61K (Preparations for medical, dental or toilet purposes) and A61P (Specific therapeutic activity of chemical compounds or medicinal preparations). Citation data from the CCD can indicate how this patent fits into the broader landscape of JAK inhibitors and related therapeutic agents[4].

Search Tools and Resources

USPTO Resources

The USPTO provides several tools for searching patents, including the Patent Public Search tool, which replaced legacy tools like PubEast and PubWest. The Global Dossier service allows users to access file histories of related applications from participating IP offices, which can be useful in analyzing the patent family and related applications[1].

International Databases

Databases like esp@cenet from the EPO, PATENTSCOPE from WIPO, and KIPRIS from the Korean Intellectual Property Rights Information Service provide access to international patent collections, enabling a thorough search for similar inventions globally[1].

Key Takeaways

  • Specific Salt Forms: The patent covers specific salt forms of the JAK inhibitor, enhancing its therapeutic efficacy.
  • Therapeutic Applications: The invention is applicable in treating cancer, skin disorders, and inflammation by modulating JAK activity.
  • Narrow Scope: The claims are detailed and specific, indicating a narrower scope that is more likely to be granted and less prone to challenges.
  • Global Reach: Searching international patent offices and using tools like the CCD can provide a comprehensive view of the global patent landscape.

FAQs

What is the main subject of United States Patent 10,610,530?

The main subject of this patent is the salt forms of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.

What are the therapeutic applications of the invention described in the patent?

The invention is used for treating diseases associated with JAK activity, including cancer, skin disorders, and inflammation.

How do the claims in this patent define its scope?

The claims define the scope by specifying the salt forms, methods of preparation, therapeutic uses, and pharmaceutical compositions, ensuring a narrow and focused scope.

What tools can be used to search for related patents internationally?

Tools like the Patent Public Search, Global Dossier, and international databases such as esp@cenet and PATENTSCOPE can be used to search for related patents internationally.

Why is the scope of the patent important?

The scope of the patent is crucial as it defines what is protected and what is not, influencing the patent's validity and enforceability. A narrower scope, as seen in this patent, can make the patent more defensible and less likely to face challenges.

How does the Common Citation Document (CCD) help in understanding the patent landscape?

The CCD consolidates prior art cited by participating IP offices, providing a single point of access to citation data related to the patent family, which helps in understanding the novelty and non-obviousness of the invention.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,610,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Incyte Corp OPZELURA ruxolitinib phosphate CREAM;TOPICAL 215309-001 Sep 21, 2021 RX Yes Yes 10,610,530*PED ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,610,530

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008266183 ⤷  Try for Free
Brazil PI0814254 ⤷  Try for Free
Canada 2689663 ⤷  Try for Free
China 101932582 ⤷  Try for Free
China 103524509 ⤷  Try for Free
Colombia 6251256 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.